(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
How a Snake That Eats Cobras Redefined the Meaning of ‘King’ - 2Meet the Artemis crew in NASA's first astronaut mission to the moon in more than a half-century
- 3Vote In favor of Your Favored Treat
- 4Historical mysteries solved by science in 2025
- 5Turkiye’s Erdogan calls Israel’s Somaliland recognition ‘unacceptable’
- Warming winters lead to more nitrate pollution in the drinking water near farms
- German diesel hits new records over Easter weekend
- Flu activity in US could continue to rise for weeks, top CDC epidemiologist says
- The Best Internet based Courses for Expertise Improvement
- The Way to Recuperation: Defeating Dependence
- Vote in favor of your Number one kind of juice
- If everyone on Earth sat in the ocean at once, how much would sea level rise?
- Anthony Joshua's driver charged over Nigeria crash that killed two
- Shas threatens to oppose 2026 state budget over haredi food-voucher exclusion
